Related Experiment Video
Updated: Jun 20, 2026
09:51
Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase
Published on: June 30, 2023
Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme
1Department of Internal Medicine, University of Pisa, Italy. ematteuc@int.med.unipi.it
Current Medicinal Chemistry
|August 20, 2009
Summary
Dipeptidyl peptidase-4 (DPP4) inhibition shows promise for type 2 diabetes but may increase infection risk. Further research is needed to understand DPP4
Area of Science:
- Biochemistry and enzymology of DPP4.
- Immunology and T-cell activation.
- Endocrinology and diabetes mellitus.
Background:
- Dipeptidyl peptidase-4 (DPP4), a serine exopeptidase, cleaves N-terminal X-proline dipeptides from various peptides.
- DPP4 is a type II transmembrane glycoprotein involved in regulating hormones like GLP-1 and GIP.
- DPP4 inhibition is a therapeutic strategy for type 2 diabetes, but potential side effects on the immune system are not fully understood.
Purpose of the Study:
- To review current knowledge on DPP4's role, particularly its implications for type 2 diabetes therapy.
- To highlight the potential impact of DPP4 inhibition on immune function and related disorders.
- To identify gaps in research regarding DPP4's immunological effects and suggest future research directions.
Main Methods:
- Literature review summarizing existing research on DPP4.
- Analysis of data from randomized controlled trials concerning DPP4 inhibitor safety.
- Exploration of DPP4's known functions in relation to immune regulation.
Main Results:
- DPP4 inhibition is effective for type 2 diabetes but may be linked to increased infections.
- DPP4 (CD26) plays a role in T-cell activation and immune-mediated disorders.
- Current safety data from clinical trials primarily focus on routine laboratory variables, not comprehensive immune effects.
Conclusions:
- DPP4 inhibitors offer a therapeutic avenue for type 2 diabetes but require careful monitoring for immune-related side effects.
- The effects of DPP4 inhibition on the immune system warrant further extensive investigation.
- Future research should focus on elucidating DPP4's precise role in immune regulation and the consequences of its inhibition.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:19Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include: